midodrine + octreotide + albumin

Midodrine + octreotide + albumin is a combination therapy investigated by the University of Padova for the treatment of hepatorenal syndrome (HRS) in patients with cirrhosis. Midodrine is a small molecule alpha-1 adrenergic agonist that induces systemic vasoconstriction to counteract the arterial vasodilation associated with advanced cirrhosis. Octreotide, a somatostatin analogue, is administered to inhibit the release of endogenous vasodilators such as glucagon, thereby reducing splanchnic blood flow. Albumin is used as a plasma volume expander to improve effective circulating volume and renal perfusion. This specific regimen was evaluated in a randomized controlled trial led by the University of Padova and published in 2015, which demonstrated that the combination was significantly less effective than terlipressin plus albumin in achieving HRS reversal.

Other names

midodrine plus octreotide plus human albuminmidodrine-octreotide-albumin